A recent publication from the RisCoin study demonstrated impaired humoral responses to COVID-19 mRNA vaccination in patients with IBD receiving immunosuppressive therapies targeting tumor necrosis factor-alpha compared to other commonly used biologics for IBD [24]. The gene discussed is TNF; the disease is inflammatory bowel disease.